To study if our anti-VEGF and anti-PDGFR combination therapy would further enhance antitumor effects of chemotherapy, we treated breast cancer and fibrosarcoma by triple combination therapy, consisting of VEGF blockade, imatinib, and 5-Fluorouracil (5-FU). Here, PDGFRB is linked to fibrosarcoma.